Rocket Pharmaceuticals, Inc., a biotechnology company based in New York, United States, has recently filed a Rule 144 notice with the Securities and Exchange Commission (SEC). This filing discloses the sale of a portion of its common stock by former officer John Militello. The transaction is scheduled to occur on September 14, 2026, and will be managed by a broker-dealer named in the document.
The Rule 144 notice provides details on the securities sold over the past three months, including the amounts involved. It also notes that a component of the sale is intended to satisfy a tax obligation related to a vested equity award. This disclosure is part of Rocket Pharmaceuticals’ adherence to regulatory reporting requirements, aimed at informing shareholders and the market about the planned transaction.
Rocket Pharmaceuticals, Inc. operates within the Health Care sector, specifically in the Biotechnology industry. The company is listed on the Nasdaq exchange and trades in USD. As of September 13, 2026, the close price of its stock was $3.43. The company’s market capitalization stands at approximately $367.74 million. Over the past year, the stock has experienced a 52-week high of $5.45 on March 9, 2026, and a 52-week low of $2.53 on June 10, 2026.
The company specializes in developing gene therapies for rare and catastrophically pediatric diseases. Despite its innovative focus, Rocket Pharmaceuticals currently reports a price-to-earnings ratio of -21.51, reflecting its financial performance and market valuation challenges.
This filing does not include any additional business updates or financial results, focusing solely on the stock sale by the former officer. The disclosure underscores the company’s commitment to transparency and regulatory compliance, ensuring that all relevant stakeholders are informed of significant corporate actions.
